Seventeen patients have undergone corneal transplantation using limbal stem cells First haploidentical stem cell transplantation has been done on the 2.4.2003. For this, CD34+ cells have been collected from the father of a child suffering from glanzmann thrombasthenia who had severe persistent bleeding. This type of transplantation is first of its kind in india. |
|
Mechanism for review and monitoring
Robust interest in stem cell treatments in India results from a unique combination of three main drivers:
(1) significant unmet health needs;
(2) high consumer demand from a large private healthcare network; and
(3) historical trust in alternative systems of medicine, which may not be evidence based.
This high level of interest in stem cell treatments also engenders ample funding for research and development of stem cell therapies through venture capitalists and through the Department of Biotechnology, which supports ∼90% of the projects.
The building blocks for regulatory approval of stem cell therapies are still in development. The Indian Council for Medical Research (ICMR) formulated guidelines for stem cell research in 2007. In particular, the ICMR has forbidden the use of embryonic cells for clinical treatment in its guidelines. However, these guidelines have not yet been converted into law and thus it is expected, but not mandatory, to register all stem cell clinical trials.
While the regulatory system is still in development, there are currently different mechanisms to regulate clinical translation, variable criteria used by oversight bodies for protection for human subjects and the ability to regulate practice of medicine separate from research.
To unify and streamline the process, the National Apex Committee for Stem Cell Research and Therapy (NAC-SCRT) was created in 2009.
NAC-SCRT is an interagency body created with the aim of effectively reviewing and monitoring stem cell research in India.
References:-
Forbes India
Department of Biotechnology,India
Stem Cell Stem